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Abstract  21 
In this study, we investigate the viability of three-dimensional (3D) inkjet printing with UV 22 
curing to produce solid dosage forms containing a known poorly soluble drug, carvedilol. 23 
The formulation consists of 10 wt% carvedilol, Irgacure 2959, and a photocurable N-vinyl-2-24 
pyrrolidone (NVP) and poly(ethylene glycol) diacrylate matrix, with the intention of forming 25 
an amorphous solid solution for release of carvedilol. Characterization of the printed tablets 26 
showed that the drug is an amorphous state and indicated hydrogen bonding interactions 27 
between the drug and cross-linked matrix. Several simple geometries (ring, mesh, cylinder, 28 
thin film) were printed, and the surface area to volume ratio of the prints was estimated. Over 29 
80% carvedilol release was observed for all printed tablet geometries within ten hours. The 30 
release behaviour of carvedilol was fastest for the thin films, followed by the ring and mesh 31 
geometries, and slowest in the cylindrical forms. More rapid release was correlated to an 32 
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increased surface area to volume ratio. This is the first study to implement 3D UV inkjet to 33 
make solid dispersion tablets suitable for poorly soluble drugs. Results also demonstrate that 34 
high drug-loaded tablets with a variety of release profiles can successfully be accessed with 35 
the same UV-curable inkjet formulation by varying the tablet geometry. 36 
 37 
1. Introduction 38 
Three-dimensional (3D) printing has been investigated as a novel route to manufacture tablets 39 
and has been shown to offer several potential benefits when compared to conventional 40 
processing methods. The FDA’s approval of Spritam, the first binder inkjet 3D printed tablet 41 
[FDA, 2015], highlighted this approach as a viable manufacturing platform to produce highly 42 
porous tablets which exhibit novel rapid drug release. 3D printing, particularly fusion 43 
deposition modelling (FDM), paste extrusion and inkjet methods, have been reported to offer 44 
manufacturing routes that enable tablet personalization through multi-active delivery [Khaled 45 
et al., 2015; Khaled et al., 2014; Genina et al., 2017; Goyanes et al., 2015b]. These 46 
techniques have also demonstrated precise control over tablet geometry and porosity, which 47 
can impart tuneable control over drug dissolution [Kyobula et al., 2017; Goyanes et al., 2015; 48 
Rowe et al., 2000; Solanki et al., 2018; Chai et al., 2017; Yang et al., 2018].  49 
3D inkjet printing is a non-contact, drop on demand printing process that has recently been 50 
investigated as a manufacturing process to produce solid oral dosage forms [Kyobula et al., 51 
2017; Clark et al., 2017]. Kyobula et al. used hot melt 3D inkjet to produce complex 52 
geometries whereby the freezing of the printed ink was the solidification process being 53 
exploited. They demonstrated with this approach how tablet geometry and infill density could 54 
be adjusted to predictably tune the release of fenofibrate, a poorly soluble drug, from a 55 
beeswax matrix.  Bioresorbable photocurable polymers have more recently been evaluated 56 
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for inkjet printing using high throughput screening. Selected UV inkjet printable paroxetine 57 
HCl loaded formulations were printed into films which exhibit long-term controlled release 58 
suitable for implant applications [Louzao et al., 2018]. Drug release behaviour of paclitaxel 59 
from solvent inkjet printed micro particle geometries has also been investigated with solvent 60 
inkjet for PLGA/dimethylacetamide formulations. Drug release was shown to rely on the 61 
ratio of surface area to print volume (SA/V) of the dosage forms [Lee et al., 2012]; this 62 
dependence has been described for FDM and SLA printed formulations [Goyanes et al., 63 
2015; Martinez et al., 2018]. Acosta-Vélez et al. have researched inkjet dispensing to deposit 64 
photocurable ink into preformed tablet reservoirs to produce dosage forms for highly water 65 
soluble drugs [Acosta-Vélez et al., 2017]. Such photocurable resin formulations have been 66 
demonstrated for VAT polymerization printing of paracetamol, 4-Aminosalicylic acid [Wang 67 
2016] acetylsalicylic acid [Vehse et al., 2014] and ibuprofen [Martinez et al., 2017]. More 68 
recently, liquid dispensing has also been combined with FDM printing to produce liquid 69 
capsules with immediate and extended release profiles for poorly soluble drugs [Okwuosa et 70 
al., 2018]. 71 
Carvedilol is a beta-blocker used to treat hypertension and heart failure [GSK, 2017]. It is 72 
nearly insoluble in water and simulated gastric fluid at pH 1.1. At pH values in the 73 
pharmaceutically relevant range of 1–8, the solubility of carvedilol in aqueous media ranges 74 
from about 0.01 to 1 mg/mL [Beattie et al., 2013]. The dissolution of carvedilol in acid 75 
medium is related to its ability to form protonated molecules [Beattie et al., 2013; Prado et al. 76 
2014]. Formulation enhancement of the solubility of carvedilol in water at 27 °C has been 77 
documented for carvedilol: para sulphonato calixarene inclusion complexes [Menon et al., 78 
2012; Beattie et al., 2013].    79 
Carvedilol is commercially available in a range of low dose immediate and sustained release 80 
doses ranging from 3.125 mg to 80 mg [GSK, 2017]. These formulations use the relatively 81 
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poorly soluble crystalline sold state forms of carvedilol [Prado et al. 2014]. As a strategy to 82 
improve the bioavailability for poorly soluble APIs the use of soluble matrix materials, such 83 
as poly(N-vinyl-2-pyrrolidone) (PVP), [Singh et al., 2017; Patterson et al., 2007; Bley et al., 84 
2010]], and poly(ethylene glycol) (PEG) [Bley et al., 2010; Chokshi et al., 2007; Singh et al., 85 
2017; Yuvaraja and Khanam, 2014] are well established pharmaceutical excipients [Singh et 86 
al., 2017, Kalepu and Mekkanti, 2015]. Photocurable analogues of PEG and PVP have also 87 
been previously investigated with 3D printing. In particular, fabrication of biomedical 88 
devices with PEG(meth)acrylate macromers have been utilized in VAT polymerization, 3D 89 
inkjet, and multiphoton polymerization printing processes [Nguyen et al., 2013; Wang et al., 90 
2016; Chan et al., 2010; Vehse et al., 2014; Ligon et al., 2017; Gu, et al., 2016; Seck et al., 91 
2010; Dhariwala et al., 2004; Gao et al., 2015; Jansen et al., 2009; Gao et al., 2015; 92 
Guvendiren et al., 2017; Clark et al., 2017; Do et al., 2018]. N-vinyl-2-pyrrolidone (NVP), 93 
the monomeric precursor to polymeric PVP, can be incorporated as a reactive diluent into UV 94 
inkjet formulations, and is capable of copolymerizing with PEG diacrylate [Lee et al., 2013]. 95 
Incorporation of NVP into copolymer networks has been shown to enhance hydrophilicity 96 
[Korsmeyer and Peppas, 1984; Caló and Khutoryanskiy, 2015; Jansen et al., 2009] in medical 97 
devices such as HEMA-co-NVP contact lenses, and NVP has been reported to solubilize a 98 
variety of both soluble and poorly soluble APIs [Hacker et al., 2009; Knopp et al., 2015]. 99 
Accelerated photocuring speeds have been reported for NVP systems, including for 3D 100 
printed PDLLA 3-FAME/NVP resins [Jansen et al., 2009], [Hacker et al., 2009] and acrylate-101 
co-NVP resins [White et al., 2006, Ergenc and Kizilel, 2011]. 102 
In our previous work we have applied inkjet with UV initiated curing as a route to 3D print 103 
tablets with controlled release of ropinirole HCl, a highly water soluble drug [Clark et al., 104 
2017]. In this study, our goal is to formulate, print and characterize a solvent-free, UV ink for 105 
3D inkjet printing a poorly soluble drug. The release behaviour, as well as the physical 106 
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properties of several printed solid dosage form geometries is therefore evaluated and 107 
compared to United States Pharmacopeia (USP) specifications. 108 
2. Materials and methods 109 
2.1. Materials 110 
Irgacure 2959 (98%) was purchased from (BASF). Carvedilol (≥ 98.5%) was purchased from 111 
Carbosynth. Poly(ethylene glycol) diacrylate (number average molecular weight, Mn = 250 112 
g/mol) and N-vinyl-2-pyrrolidone (> 99%) were purchased from Sigma-Aldrich. All 113 
materials were used as received. 114 
2.2. Characterization of solid dosage dimensions 115 
The dimensions of the printed dosages were measured with an electronic caliper (Products 116 
Engineering Corp.). 117 
2.3. X-ray micro computed tomography (CT) scanning 118 
CT scanning of the dosage forms was carried out on a Nikon micro CT scanner (Derby, 119 
UK) with typical x-ray beam settings of 51kV and a 92 mA current, 1000 ms exposure time, 120 
two frames, and 3142 projections. Samples were mounted on a foam sample holder. No 121 
filtering was implemented, and the calculated scan resolution was 6.2 m. The Nikon CT-Pro 122 
software was used to reconstruct the samples. VGSTUDIO MAX (Volume Graphics, 123 
Heidelberg, Germany) software was used to remove the foam, visualize, and measure the 124 
printed dosage forms. 125 
2.4. FTIR-ATR spectroscopy 126 
Samples were analysed with a Perkin Elmer Frontier FTIR-ATR spectrometer (Seer Green, 127 
UK) from 4000 cm
−1
 to 600 cm
−1





Three scans were collected for each sample. Prior to sample spectrum collection, a 129 
background was collected on the clean ATR crystal.  130 
2.5. Raman spectroscopy 131 
A LabRAM HR (Northhampton, UK) confocal Raman microscope equipped with a 784 nm 132 
infrared laser, 600 nm grating, 300m slit width, and 50x objective microscope lens was 133 
used to collect single point Raman spectra. Two accumulations were taken per scan with a 134 
20s total acquisition time and spectra were analysed with the Horiba Scientific Jobin Yvon 135 
Lab Spec 6 Software.  136 
2.6. Dissolution testing with HPLC characterization  137 
Dissolution testing was performed using a Copely Scientific (Nottingham, UK) Tablet 138 
Dissolution Tester DIS 8000 according to USP specifications for carvedilol [USP, 2011] with 139 
rotating USP I baskets. The dissolution media was composed of 0.7 mL/L hydrochloric acid 140 
(HCl) diluted in ultra-pure water (=18.2 MΩ.cm, ELGA), adjusted to pH 1.5 with a 50 wt% 141 
NaOH aqueous solution. The test was performed at constant volume in 900 mL of dissolution 142 
media at 37

C. Throughout the dissolution test, five millilitre sample aliquots were removed 143 
at predetermined times and replaced with fresh media in order to maintain constant volume, 144 
then filtered with a 0.45 m Millex PTFE hydrophilic filter (Millipore Ltd. Hertfordshire, 145 
UK).  146 
Samples were characterized with an Agilent (Santa Clara, USA) HPLC Series 1100 system, 147 
equipped with an auto sampler, degasser and UV lamp. A wavelength of 240 nm was used to 148 
quantify the API. Method mobile phase compositions were 65% phosphate buffer and 35% 149 
acetonitrile (Fisher HPLC gradient grade). Phosphate buffer was composed of 2.72 g/L 150 
monobasic potassium phosphate (anhydrous, Sigma Aldrich) adjusted to pH 2.0 with 151 
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phosphoric acid (85-90%, Fluka). A Supelco (Sigma Aldrich) C18 Discovery column (5 m, 152 
25 cm x 4.6 mm diameter) was used to separate the samples at 35
o
C. A flowrate of 1.3 153 
ml/min using a 20L injection volume was implemented; runtime was 20 min. Carvedilol 154 
stock solutions were prepared according to the USP method [USP, 2014] by sonicating 155 
carvedilol (nominally 7 mg, Carbosynth) in 5 mL methanol (Fisher HPLC grade) and diluting 156 
the volume with dissolution media in a 250 mL volumetric flask. Standards were prepared 157 
with the stock solution and dissolution media.  The standard calibration curve is included in 158 
the supplementary section, Fig. A.1. This HPLC method was also implemented to determine 159 
the initial carvedilol content in each printed geometry. Samples were leached separately in 160 
250 mL dissolution media in volumetric flaks, sealed with Para film and magnetically stirred 161 
at room temperature. After two days, the samples were filtered (0.45 m) and analysed for 162 
carvedilol content.  163 
2.7. Ink fluid properties characterization 164 
A Kruss GmbH (Hamburg, DE) Drop Shape Analyser DSA100 was used to evaluate the 165 
surface tension of the ink at ambient temperature with the Pendant Drop Method. The drop 166 
shape was analysed with the Kruss analysis software, with the Laplace-Young equation.  167 
A Malvern (Malvern, UK) Kinexus rheometer fit with a cup and bob geometry was used to 168 
characterize the ink viscosity. 169 
2.8. Dosage form leaching in ethyl acetate  170 
Leaching of the printed geometries was carried out at room temperature in ethyl acetate 171 
(VWR, 99.9%). Samples were leached for two days in 20 mL ethyl acetate, with the media 172 
changed daily. After two days a final wash with 10 mL ethyl acetate was carried out for thirty 173 
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minutes. Samples were dried in a vacuum oven overnight at 50
º
C and stored in a vacuum 174 
desiccator. 175 
2.9. HPLC characterization of carvedilol and NVP content in printed, leached samples 176 
The carvedilol and NVP content of the leached samples was determined with the USP HPLC 177 
method. NVP standards and samples were prepared in acetonitrile (Fisher, HPLC gradient 178 
grade). Printed samples were leached separately in 50mL Para film sealed volumetric flasks 179 
for two days at room temperature with magnetic stirring. A calibration curve for NVP (Fig. 180 
A.1) and a carvedilol standard (110 ppm) were prepared. Samples and the standard(s) were 181 
analysed for carvedilol content with HPLC using an injection volume 5 L. A 20 L 182 
injection volume was implemented for NVP. Representative HPLC chromatograms of the 183 
samples and scans are included in the supplementary section, Fig. A.3. 184 
2.10. Preparation of the printing ink 185 
A drug containing ink solution with 0.50 wt% Irgacure 2959 (BASF), 10.00 wt% carvedilol 186 
(Carbosynth), 73.06 wt% NVP (Sigma Aldrich > 99%), 16.44 wt% PEGDA (Mn= 250 g/mol, 187 
Sigma-Aldrich) was prepared by stirring the mixture at 25
o
C until dissolved. The mole ratio 188 
of NVP to PEGDA was fixed to 10:1. The curing behaviour of a series of NVP:PEGDA ink 189 
compositions was also determined by photocalorimetry and is included in Table A.1 and 190 
Fig. A.4. The ink was filtered using a 0.45m hydrophilic PTFE filter, sealed with a septum, 191 
degassed with N2 (g), and loaded into a Dimatix 10pL print cartridge with a syringe. To 192 
prevent premature ink exposure to ambient light, cartridge loading was carried out in a dark 193 
room and the cartridge was wrapped several times in silver duct tape. 194 
2.11. Ink printing parameters and BMP images 195 
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The carvedilol ink formulation was printed with a Dimatix DMP 2830 (Fujifilm Dimatix, 196 
Inc., Santa Clara, USA) printer equipped with a 365 nm (695 mW/cm
2
, UV lamp, Printed 197 
Electronics PEL Tamworth, UK) lamp bolted to the print assembly and in line with the print 198 
path as previously described in [He et al., 2017] and [Clark et.al, 2017]. The printer was 199 
enclosed in a custom-built glove box and purged with N2 (g), and oxygen levels were kept 200 
below 0.2%. The jetting firing voltage was 17-19.8V with a 3 kHz frequency and a drop 201 
speed adjusted to 1.00 mm in 130 s. All samples were printed at ambient temperature. 202 
Twenty non-jetting, UV post-curing layers were implemented for all print runs to further cure 203 
the dosage forms. Print specific parameters for each batch of dosage geometries such as the 204 
BMP digital image file used per layer, and the number of layers printed are tabulated in 205 
Table 1. The number of jets used ranged from 13 to 16, the maximum number of jets on the 206 
cartridge. 207 
 208 
3. Results and Discussion 209 
3.1. Ink characterization  210 
The fluid flow properties of the ink were characterised and found to be suitable for printing. 211 
The operating ink viscosity and surface tension ranges for printing quoted by Dimatix are 2-212 
12 centipose (cP) and 20-40 mN/m respectively [Fujifilm, 2008]. The measured ink viscosity 213 
was 4.50 +/- 0.01 cP (20

C, n=3) and the surface tension of the ink was 36.13 +/- 0.55 mN/m 214 
at ambient temperature (21.85

C, n=10), indicating the ink is within the recommended 215 
viscosity and surface tension ranges for the Dimatix printer. 216 
3.2. Physical characterization of the printed dosage form geometries 217 
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Images of the printed geometries are included in Figs. 1a, 1d , 1e and the digital BMP files 218 
are illustrated in Fig. 1c. The printed geometries were robust (non-fragile), and easily 219 
handled. They appeared translucent and slightly yellow. In comparison, the formulated 220 
solutions were clear and slightly yellow, similar in appearance to the NVP liquid monomer.  221 
Optical microscopy (Fig. 1a) and the images indicate that the top surface of the tablets was 222 
topographically non-uniform; with bands corresponding to an individual print pass observed 223 
on the surface. In some cases, the deposition of excess ink (ring and thin film geometries, 224 
Fig. 1d,e) was also observed on the top surface, suggesting some leaking of the ink from the 225 
nozzle plate during printing. No evidence of crystallization within the dosage form (ijpr002) 226 
was observed in cross-polarized optical microscopy (Fig. 1b) or DSC. Melting peaks were 227 
not observed in the DSC thermogram of the solid dosage form, providing further evidence 228 
that carvedilol is an amorphous form within the printed polymeric matrix (Fig. A.5).  229 
The thickness and diameter of the printed tablets are summarized in Table 1, as well as the 230 
digital image file dimensions. Tablet mass deviations were low, and no percent mass 231 
deviations exceeded USP specifications within each batch (10%, tablets <80 mg, USP 2000). 232 
Percent weight deviation for each tablet and all geometries is included in Table A.2. Tablet 233 
heights and diameters were also consistent. However, the dimensions of the tablets were 234 
observed to be larger than the image file specifications (up to 13%), as a result of the print 235 
resolution employed. The cause of these dimensional inconsistencies is unclear and may be 236 
attributed to ink spreading and variable ink curing speeds per batch. Free radical acrylate 237 
curing can be affected by the UV intensity or increased oxygen levels in the printing 238 
environment [Wight and Nunez, 1989].  The SA, V and SA/V ratio values for the dosages 239 
(Table 2) were calculated from the dimensional data in Table 1. The thin film geometries 240 
had the largest SA/V ratio, followed by the ring and cylindrical geometries. 241 
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An STL file (Fig. A.6) was then generated for each geometry from the digital bitmap image. 242 
The height of each geometry was estimated using the number of layers printed and the 243 
thickness per layer. The thickness per layer was determined from the measured height of the 244 
cylindrical tablets (ijpr002). It should be noted that the STL files represent only the intended 245 
dimensions, surface area, and volume of the printed geometries, and that the volume was kept 246 
constant. The SA, V and calculated SA/V ratios from the STL files are tabulated in Table 2. 247 
3.3. FTIR-ATR characterization of the dosage forms 248 
FTIR-ATR of the printed tablets (ijpr002, non-leached) suggests a high degree of curing in 249 
the dosage forms and the formation of a cross-linked network. The significant reduction in 250 
the PEGDA related acrylate double bond peaks (=CH2 twist 810 cm
-1
), and the NVP vinyl 251 
group (at 1629 cm
-1
), suggest extensive Michael addition of the double bond and thus 252 
indication of the formation of a cross-linked polymer. A broad ester carbonyl peak from the 253 
cross-linked PEGDA is observed at 1729 cm
-1
, and the peak at 1666 cm
-1
 is assigned to the 254 
amide C=O stretch of PVP. The assignment of the peak observed in the spectra at 1629 cm
-1
 255 
is unresolved, as this can be attributed to the vinyl stretch of residual NVP and the aromatic 256 
C=C stretch of the drug. The characteristic aryl C=C stretches for carvedilol at 1608 cm
-1
 and 257 
1591 cm
-1
 are observed in the tablets at 1607 cm
-1
 and 1589 cm
-1
, respectively, indicating the 258 
incorporation of the drug into the dosage. Furthermore, a strong, broad peak at 3457 cm
-1
 259 
indicates hydrogen bonded interactions in the cured dosage form.   260 
For comparison, the FTIR spectrum of the drug-loaded ink is included in Fig. 2a. The 261 
characteristic C=C vinyl group stretch of NVP is observed at 1626 cm
-1
 and the peak 262 
observed at 1697 cm
-1 
is assigned to the C=O (amide) of NVP. A distinct characteristic C=O 263 
(ester) shift for the PEG acrylate functional group is not observed, and possibly is overlapped 264 





while, the characteristic saw-tooth shaped, secondary amine N-H stretch of carvedilol (3342 266 
cm
-1
) and the overlapping OH stretch are notably absent from the spectra, suggesting strong 267 
interactions between the carrier NVP-PEGDA ink and carvedilol. The broad (weak) peak at 268 
approx. 3392 cm
-1
 is attributed to hydrogen bonding [Lin-Vien et al., 1991]. 269 
3.4. Confocal Raman characterization of the dosage forms 270 
Further characterization with Raman spectroscopy (Fig. 2b) confirmed the presence of 271 
carvedilol in the tablets. Assignments for the carvedilol were made in accordance with those 272 
reported by Marques et al., 2002. The carvedilol spectra exhibit a pyrrole ring breathing 273 
mode peak at 427.5 cm
-1
, an N-H bend at 727.6 cm
-1
, a C=C stretch/ring breathing peak at 274 
1013.4 cm
-1






, and 275 
characteristic peaks at 550.4 cm
-1
 and 1285.6 cm
-1 
(strong). The printed tablets exhibit API-276 















 and 1628.4 cm
-1
, further confirming the presence of carvedilol in the solid 278 
dosage form. Similar to the FTIR-ATR spectra of the tablet, the peak at 1628.4 cm
-1
 may be 279 
attributed to carvedilol (C=C stretching, aromatic) and unreacted NVP (C=C stretch) in the 280 






, with the latter assigned to unreacted NVP. 282 
3.5. Assay of the carvedilol content and residual monomer in the leached dosage forms 283 
The materials palate for UV inkjet printing of pharmaceuticals is limited and persistence of 284 
residual unreacted material after UV curing is problematic, as residual unreacted monomer in 285 
the printed dosage forms is a concern due to possible toxicity [Norman et al., 2017]. The USP 286 
and FDA specify limits for unreacted NVP monomer in PVP based products with NVP 287 
content limited to 0.1 wt% in PVP copolymer (copovidone [USP, 2006a, b]) and cross-linked 288 
PVP (crospovidone) and 0.0001 wt% (10ppm) in pharmaceutical grade PVP (Povidone, 289 
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[USP, 2006c]). Furthermore, the FDA limits the amount residual monomer in PVP used in 290 
food additive applications to 1 wt% [FDA, 2017]. A post-processing leaching procedure was 291 
therefore implemented to remove unreacted monomer from the printed geometries. Ethyl 292 
acetate was selected to leach NVP from the printed dosages, as this solvent is miscible with 293 
NVP and PEGDA, exhibits low toxicity [FDA, 2017b], and can be readily removed. Cross-294 
linked PEGDA and PVP are insoluble in ethyl acetate, and carvedilol exhibits low solubility 295 
in this solvent [Ha et al., 2019]. The final amount of unreacted NVP and recovered API for 296 
each printed geometry is summarized in Table 3. The dosage forms lost 5.4% to 10% of their 297 
original mass during leaching, and it should be noted that carvedilol, as well as NVP can be 298 
leached during this process (loss of carvedilol is between 2.3 wt% and 12.6 wt%). The 299 
residual NVP monomer concentrations in the leached ring, mesh and film geometries were 300 
shown to be within the USP limits for crospovidone and copovidone (0.1 wt%). The 301 
cylindrical tablets exhibited NVP content (0.18 wt%, by HPLC) above the USP limits for 302 
copovidone and crospovidone (0.1 wt%), but still within the FDA limit for PVP (1%) for 303 
food applications. Overall, drug loading in the dosage forms remains relatively high after 304 
leaching, and further experiments could be carried out to determine if lower residual NVP 305 
targets could be achieved on shorter timescales by implementing other solvents, or with 306 
longer leaching times in ethyl acetate. 307 
3.6. Dissolution of the leached dosage forms 308 
The USP and FDA guidance for carvedilol tablets and extended release carvedilol phosphate 309 
capsules specifies HCl(aq) dissolution medium [FDA, 2017c; USP, 2011] so as to promote 310 
sufficient drug solubility (via protonation) to allow analysis of released drug, and dissolution 311 
of the dosages was hence performed according to USP conditions for the printed carvedilol 312 
tablets.  313 
14 
 
There is an improvement in carvedilol solubility at lower pH because the drug ionizes, but it 314 
still meets the qualification for being an insoluble API (0.033 mg/ml in 0.1M HCl [Beattie et 315 
al., 2013] and 0.089 mg/ml in 0.1M HCl [Shah et al., 2011]). The dissolution profiles (Fig. 3) 316 
demonstrated over 80% carvedilol release, despite the relatively high loading (10 wt%) for all 317 
printed tablet geometries within ten hours, and complete release within twenty hours. The 318 
dosages were observed to swell during dissolution (and the assay) and did not remain intact 319 
(Fig. A.2). Release was fastest for the thin films, followed by the ring and mesh geometries, 320 
and slowest for the cylindrical dosage forms. Faster release correlated to an increased surface 321 
area to volume ratio (SA/V) for the geometries (thin film > ring > cylinder) as calculated 322 
from the data in Table 2, showing that the formulation surface area is a controlling factor in 323 
release rate rather than any mechanism related to disintegration. This trend is in agreement 324 
with the literature [Lee et al., 2012; Goyanes et al., 2015; Martinez et al., 2018].  Similarly, 325 
the residual NVP content (Table 3), was lowest in the dosages with higher SA/V ratios, 326 
suggesting also that the leaching of the monomer may also be influenced by this ratio. 327 
CT imaging of the solid dosage forms 328 
The surface area and volume of the cylindrical and mesh carvedilol dosages were 329 
characterized with CT scanning imaging (Table 4). The CT scans of the dosage forms are 330 
illustrated in Fig. 4. Pores were not observed in the CT scans, suggesting the dosage forms 331 
are compact. Table 4 indicates that the volume of the mesh dosage forms decreases after 332 
leaching by 8.81%. Given the density of NVP (1.04 g/mL), this volume decrease corresponds 333 
to an approximate mass loss of 9.16% and is comparable to the mass loss noted in Table 2 334 
for the mesh dosage forms. The volume of the cylindrical geometry measured with CT is 335 
lower than that calculated based on manual measurement (Table 2) and similarly, the CT 336 
measured surface area was larger than that calculated in Table 2. It should also be noted that 337 
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the resulting SA/V values for the cylindrical tablets calculated with the CT imaging data are 338 
larger (by 213%) than those calculated in Table 2. These differences can be understood in 339 
terms of the volume shrinkage exhibited by photocurable materials during curing [Park et al., 340 
2016] and an increased surface roughness resulting from the printing process.   341 
4. Conclusions 342 
Inkjet printing is a precise and scalable manufacturing method that can be used to produce 343 
pharmaceutical dosage forms. In this study, we demonstrate the feasibility of 3D inkjet 344 
printing a relatively highly drug-loaded (10 wt%) UV curable formulation for a poorly 345 
soluble API.  The solid dosages were composed of carvedilol in a hydrophilic NVP and 346 
PEGDA cross-linked matrix. Several dosage geometries were printed and the release speed of 347 
carvedilol was characterized (thin films > ring, mesh>cylinder), thereby demonstrating 348 
different release profiles which can be accessed with a single ink. The weight variation of the 349 
printed solid dosages met USP specification. The release speed was demonstrated to increase 350 
with increased surface area to volume (SA/V) ratio for a cylindrical tablet to a mesh and ring 351 
geometry, to a thin film dosage form. The Raman and FTIR-ATR characterization of the 352 
tablets confirm the presence of an amorphous form of the drug in the tablets and suggest 353 
strong hydrogen bonding between the drug and the matrix. Finally, a post-processing 354 
leaching method to remove unreacted monomer in the printed dosage forms was investigated. 355 
Residual levels of monomer after leaching were demonstrated to be within the USP and FDA 356 
targets levels (0.1% for PVP related excipients copovidone and crospovidone) for several 357 
geometries (ring, film, mesh).  358 
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Cylinder    
ijpr010**** 
Thin Film**** Ring Mesh **** 
BMP Geometry circle circle square ring mesh 
BMP dimensions (mm) 7.02 7.02 11.01 x 11.01 8.49 8.52 
Print dimensions (mm) 7.04 ± 0.01 7.75 ± 0.03* 12.51 ± 0.05 x 12.45 
± 0.04 
 
9.27 ± 0.02 x 9.45 ± 
0.03  (n=7)** 
9.31 ± 0.04 x 9.14 ± 
0.04 
Deviation of print from 
BMP file (%) 
 
0.2279 ± 0.13 10.4 4± 0.41 13.08 ± 0.58  - 13.61 
± 0.41 
10.27 ± 0.25 (n=7) 7.22 ± 0.51 
Print height (mm) 1.62 ± 0.01 1.41 ± 0.03* 0.56 ± 0.03 1.53 ± 0.03 (n=7) 1.54 ± 0.04 
No. layers printed 200 200 64 188 160 
Cartridge height (mm) 1 2 1 1 1 
No. jets used  16 16 16 13 15 
      
Mass (mg) 50.97 ± 0.15 50.68 ± 0.35 (n=13) 53.87 ± 0.44  (n=12) 50.80 ± 0.14 (n=9) 59.61 ± 0.51 (n=12) 
 
* measured after leaching in ethyl acetate  
** Case wall thickness: 2.34+/- 0.01 (n=2). Case wall thickness of BMP image file was 2.00mm.  
*** n=15 for all measurements 
*** *n=10 for all measurements unless specified 
 
Table(1)






Thin Film**** Ring Mesh **** 
Print volume, V (mm3) 62.94 ± 0.46 66.57 ± 1.57 87.20 ± 3.47 79.50 ± 0.21 - 
Print Surface area, SA (mm2) 113.5 ± 0.4 128.8 ± 1.0 339.4 ± 2.4 171.05 ± 0.29 (n=2) - 
Print SA/V ratio (mm-1) 1.804 ± 0.009 1.934 ± 0.034 3.897 ± 0.146 2.151 ± 0.009 (n=2) - 
Height of STL (mm) 1.62 1.62 0.518 1.523 1.296 
Calculated V from STL (mm3) 62.693 62.693 62.768 60.277 62.596 
Calculated SA from STL (mm2)  113.127 113.127 265.244 141.783 176.719 
Calculated SA/V ratio from STL 
(mm-1) 
1.8 1.8 4.23 2.35 2.82 
 
* measured after leaching in ethyl acetate  
** Case wall thickness: 2.34+/- 0.01 (n=2). Case wall thickness of BMP image file was 2.00mm.  
*** n=15 for all measurements 
*** *n=10 for all measurements unless specified 
 
Table(2)
Table 3: HPLC measurement results for the leached printed tablets 
 
*Calculation based on carvedilol detected and the dried, final leached mass 
** Calculated with (mass NVP detected) / (final leached mass - amount of API detected) x 100 












Carvedilol dose per dosage form (mg) 4.68 ± 0.10 4.63 ± 0.05 5.44 ± 0.06 4.44 ± 0.04 
Percent carvedilol loading (%)* 10.3 ± 0.1 9.65 ± 0.06 9.85 ± 0.04 9.16 ± 0.04 
NVP monomer detected by HPLC (mg) 0.076 ± 0.015 0.025 ± 0.001 0.017 ± 0.001 0.011 ± 0.002 
Percent NVP in dosage form (wt%) ** 0.178 ± 0.037 0.057 ± 0.001 0.035 ± 0.002 0.026 ± 0.005 
Total mass loss after drying and leaching (%) 5.92 ± 0.26  5.41 ± 0.32 7.29 ± 0.05 9.95 ± 0.58 
Carvedilol detected in non-leached printed dosage (mg)  4.79 ± 0.06 5.18 ± 0.01 5.98 ± 0.02 5.08 ± 0.04 
Table(3)









Cylinder 11, leached (ijpr010) 38.9 160.37 4.12 
Mesh 5, leached (ijpr005) 44.5 278.61 6.26 
Mesh  14, non-leached (ijpr005) 48.8 267.48 5.48 
Table(4)
Fig. 1.  Images of the printed geometries. a) Optical microscopy (reflection) and b) cross 
polarized optical microscopy (transmission) of a cylindrical tablet c) BMP 2D images used to 
build the 3D geometries d) images of dosages printed (top scale in mm) e) images of the 
tablets after leaching and drying. The scale is in mm. 
Fig. 2. Spectroscopic characterization of the starting materials and dosage forms. a) FTIR-
ATR for the printed cylindrical tablets (n=10 scans), PEGDA, NVP, the carvedilol loaded ink 
formulation, and carvedilol b) confocal Raman microscopy of a leached cylindrical tablet 
(blue), a cylindrical tablet (black), a drug free (API-free) tablet (grey) and carvedilol (red). 
Fig. 3. Release behaviour of carvedilol from the printed dosage forms in USP (pH 1.5) HCl 
dissolution media. Error bars indicate standard deviation. n=4 for cylindrical geometries and 
n=3 for thin film, mesh and ring geometries.  
Fig. 4. CT Images of the dosage forms. a) A leached cylindrical tablet (ijpr010) b) a leached 
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